OncoGenex Pharmaceuticals

Type: Company
Name: OncoGenex Pharmaceuticals
First reported Oct 17 2014 - Updated Oct 17 2014 - 1 reports

Vasectomy Docs Participate in 2nd Annual World Vasectomy Day

BioMedReports Active Stocks: Merck & Co, OncoGenex Pharmaceuticals, Ibio Inc, Orasure, AbbVie Inc: U.S. stocks returned to ... http://t.co/TIWQgHYT4r ... [Published BioMedReports - Oct 17 2014]
First reported Oct 16 2014 - Updated Oct 16 2014 - 1 reports

Active Stocks: Merck & Co, OncoGenex Pharmaceuticals, Ibio Inc, Orasure, AbbVie Inc

U.S. stocks returned to the red Thursday afternoon, after clawing back from sharp early losses in a day of seesaw trading.The Dow Jones Industrial Average was down 38 points, or 0.2%, to 16103. The blue-chip index had fallen as many as 206.52 points earlier ... [Published BioMedReports - Oct 16 2014]
First reported Oct 16 2014 - Updated Oct 16 2014 - 2 reports

OncoGenex to Report Financial Results for Third Quarter 2014 on October 30, 2014

BOTHELL, Wash. and VANCOUVER, British Columbia, Oct. 16, 2014 /PRNewswire/ -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that the Company's third quarter 2014 financial results will be released on Thursday, October 30, 2014, and ... [Published PR Newswire: Financial Services - Oct 16 2014]
First reported Oct 09 2014 - Updated Oct 09 2014 - 1 reports

Global Non-small Cell Lung Cancer market to grow at a CAGR of 3.62 percent over the

(live-PR.com) - Analysts recognize the following companies as the key players in the Global Non-small Cell Lung Cancer Market: AstraZeneca plc, Celgene Corp., Eli Lilly and Co., F. Hoffmann-La Roche Ltd. and Pfizer Inc. Other prominent vendors in the ... [Published Live-PR.com - Oct 09 2014]
First reported Oct 07 2014 - Updated Oct 07 2014 - 1 reports

Teva scales back R&D as Copaxone competition looms

Teva is dropping its R&D programmes in cancer and women's health in order to focus on central nervous system and respiratory diseases.The Israeli company says it intends to trim around $150m off its R&D budget next year, rising to $200m in 2016 and 2017, ... [Published PMLive - Oct 07 2014]
First reported Sep 20 2014 - Updated Sep 20 2014 - 1 reports

OncoGenex Pharmaceuticals Reaches New 12-Month Low at $2.76 (OGXI)

OncoGenex Pharmaceuticals (NASDAQ:OGXI) hit a new 52-week low during trading on Friday , reports. The stock traded as low as $2.76 and last traded at $2.81, with a volume of 355,570 shares. The stock had previously closed at $3.00.The stock’s 50-day moving ... [Published American Banking News - Forex - Sep 20 2014]
First reported Sep 18 2014 - Updated Sep 18 2014 - 1 reports

OncoGenex's Phase III Prostate Cancer Study Fully Enrolled

Pipeline updates are highly awaited events in the pharma/biotech sector as they play an important role in deciding whether or not to invest in a particular company. These updates provide information on experimental drugs and at times give an insight into ... [Published Zacks.com - Sep 18 2014]
First reported Sep 16 2014 - Updated Sep 16 2014 - 2 reports

OncoGenex Completes Patient Enrollment In Phase 3 Trial Of Custirsen

OncoGenex Pharmaceuticals, Inc. (OGXI: Quote) Tuesday said it has finished patient enrollment in its Phase 3 AFFINITY trial, which evaluates the potential of Custirsen to improve survival outcomes in men with metastatic castrate-resistant prostate cancer ... [Published RTTNews.com - Sep 16 2014]
First reported Aug 21 2014 - Updated Aug 22 2014 - 1 reports

OncoGenex Announces Update on Phase 3 ENSPIRIT Trial Evaluating Custirsen in Advanced Non-Small Cell Lung Cancer

BOTHELL, Wash. and VANCOUVER, British Columbia, Aug. 21, 2014 /PRNewswire/ -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that the Phase 3 ENSPIRIT trial, evaluating custirsen in the treatment of non-small cell lung cancer (NSCLC), ... [Published PR Newswire: Health - Aug 21 2014]
First reported Aug 22 2014 - Updated Aug 22 2014 - 1 reports

OncoGenex Says Lung Cancer Drug Trial Will Continue

OncoGenex Pharmaceuticals Inc. Related Biotechnology, Pharmaceutical and Healthcare NewsOriginal Article: NEXT ARTICLE More From BioPortfolio on "OncoGenex Says Lung Cancer Drug Trial Will Continue"Search BioPortfolio ... [Published BioPortfolio - Aug 22 2014]
First reported Aug 07 2014 - Updated Aug 08 2014 - 1 reports

OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Second Quarter 2014

BOTHELL, Wash. and VANCOUVER, British Columbia, Aug. 7, 2014 /PRNewswire/ -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today provided a summary of clinical developments and announced second quarter 2014 financial results.Clinical Developments and ... [Published PR Newswire: Health - Aug 07 2014]
First reported Apr 28 2014 - Updated Apr 29 2014 - 3 reports

OncoGenex Phase 3 prostate cancer trial fails

Top-line survival results of OncoGenex Pharmaceuticals’ (NASDAQ:OGXI) Phase 3 SYNERGY trial indicate that the addition of custirsen to standard first-line docetaxel/prednisone therapy did not meet the primary endpoint of a statistically significant improvement ... [Published BioPortfolio - Apr 29 2014]

Quotes

...and has reached late-stage testing in prostate and lung cancer, and Teva said in its latest statement that in oncology and women's health it would "focus on market-ready or close-to-market assets to maximize sustainable profitability."
"We are grateful to the AFFINITY investigators for their efforts, as well as the patients and their loved ones who are supporting this important trial. The pace of enrollment over the past six months has been a strong indication of the prostate cancer community's ongoing interest in custirsen, particularly in more heavily treated patients, like those in the AFFINITY trial" said Scott Cormack
...Second, there has been no word on the next steps toward approval, other than chief operating officer Julie Smith's statement:  "We plan to meet with regulators soon for the purpose of defining the next step toward the potential approval of RP103 for Huntington's disease in the U S and Europe."
NEXT ARTICLE More From BioPortfolio on "OncoGenex and Teva’s prostate cancercancer drug fails in Ph III study"

More Content

All (45) | News (35) | Reports (0) | Blogs (7) | Audio/Video (0) | Fact Sheets (0) | Press Releases (3)
sort by: Date | Relevance
Vasectomy Docs Participate in 2nd Annual World ... [Published BioMedReports - Oct 17 2014]
Active Stocks: Merck & Co, OncoGenex Pharmaceut... [Published BioMedReports - Oct 16 2014]
OncoGenex to Report Financial Results for Third... [Published PR Newswire: Financial Services - Oct 16 2014]
OncoGenex Pharmaceuticals : to Report Financial... [Published 4 Traders - Oct 16 2014]
Global Non-small Cell Lung Cancer market to gro... [Published Live-PR.com - Oct 09 2014]
Teva scales back R&D as Copaxone competition looms [Published PMLive - Oct 07 2014]
Ureter Cancer Treatment Market - Global Industr... [Published MyNewsDesk - Sep 26 2014]
OncoGenex Pharmaceuticals Reaches New 12-Month ... [Published American Banking News - Forex - Sep 20 2014]
OncoGenex's Phase III Prostate Cancer Study Ful... [Published Zacks.com - Sep 18 2014]
Ample room available for novel products in meta... [Published European Pharmaceutical Review - Sep 18 2014]
Global Non-small Cell Lung Cancer Market : 2014... [Published MarketResearch.com - Sep 17 2014]
OncoGenex Completes Patient Enrollment In Phase... [Published RTTNews.com - Sep 16 2014]
OncoGenex Announces Completion of Patient Enrol... [Published ADVFN UK - Sep 16 2014]
OncoGenex Announces Completion of Patient Enrol... [Published Financial Services - Sep 16 2014]
Studies Help Refine Management of Prostate Cancer [Published The ASCO Post - Sep 15 2014]
4 Under-$10 Biotech Stocks in Breakout Territory [Published The Street Latest - Aug 27 2014]
OncoGenex Says Lung Cancer Drug Trial Will Cont... [Published BioPortfolio - Aug 22 2014]
OncoGenex Announces Update on Phase 3 ENSPIRIT ... [Published PR Newswire: Health - Aug 21 2014]
Why Raptor Is Down, Despite Possibility of New ... [Published The Street Latest - Aug 14 2014]
4 Stocks Under $10 Making Big Moves [Published The Street Latest - Aug 08 2014]
OncoGenex Pharmaceuticals, Inc. Reports Financi... [Published PR Newswire: Health - Aug 07 2014]
OncoGenex Pharmaceuticals Announces Appointment... [Published PR Newswire: General Business - Aug 07 2014]
Squamous NonSmall Cell Lung Cancer Pipeline Re... [Published BioPortfolio - Aug 06 2014]
OncoGenex to Report Financial Results for Secon... [Published PR Newswire: Health - Jul 24 2014]
OncoGenex Announces Cedar™ Clinical Trial Evalu... [Published PR Newswire: Health - Jul 01 2014]
Boeing boss didn’t make our list, but did top a... [Published Seattle Times - Jun 29 2014]
OncoGenex raises $24 million [Published BioPortfolio - Jun 28 2014]
OncoGenex Pharmaceuticals Announces Pricing of ... [Published Financial Services - Jun 26 2014]
Transitional Cell Cancer Urothelial Cell Cancer... [Published BioPortfolio - May 28 2014]
OncoGenex Retrenches and Searches for Answers A... [Published BioPortfolio - May 22 2014]
1 2
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
OncoGenex to Report Financial Results for Third... [Published PR Newswire: Financial Services - Oct 16 2014]
BOTHELL, Wash. and VANCOUVER, British Columbia, Oct. 16, 2014 /PRNewswire/ -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that the Company's third quarter 2014 financial results will be released on Thursday, October 30, 2014, and ...
OncoGenex Announces Update on Phase 3 ENSPIRIT ... [Published PR Newswire: Health - Aug 21 2014]
BOTHELL, Wash. and VANCOUVER, British Columbia, Aug. 21, 2014 /PRNewswire/ -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that the Phase 3 ENSPIRIT trial, evaluating custirsen in the treatment of non-small cell lung cancer (NSCLC), ...
OncoGenex Pharmaceuticals, Inc. Reports Financi... [Published PR Newswire: Health - Aug 07 2014]
BOTHELL, Wash. and VANCOUVER, British Columbia, Aug. 7, 2014 /PRNewswire/ -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today provided a summary of clinical developments and announced second quarter 2014 financial results.Clinical Developments and ...
OncoGenex Pharmaceuticals Announces Appointment... [Published PR Newswire: General Business - Aug 07 2014]
BOTHELL, Wash. and VANCOUVER, British Columbia, Aug. 7, 2014 /PRNewswire/ -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today announced the appointment of John A. Bencich as Vice President and Chief Financial Officer (CFO).  John Bencich, an experienced ...
OncoGenex to Report Financial Results for Secon... [Published PR Newswire: Health - Jul 24 2014]
BOTHELL, Wash. and VANCOUVER, British Columbia, July 24, 2014 /PRNewswire/ -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that the Company's second quarter 2014 financial results will be released on Thursday, August 7, 2014, and that ...
1 2

Press Releases

sort by: Date | Relevance
OncoGenex Announces Completion of Patient Enrol... [Published Financial Services - Sep 16 2014]
OncoGenex Pharmaceuticals Announces Pricing of ... [Published Financial Services - Jun 26 2014]
OncoGenex Pharmaceuticals, Inc. Reports Financi... [Published Financial Services - Apr 30 2014]
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.